

Supplementary Table S1. Best response to fluoropyrimidine–platinum doublet plus trastuzumab according to baseline NK cell activity among patients with measurable disease (n=29)

	Low baseline NK cell activity (n=14)	High baseline NK cell activity (n=15)	P value
Best response			>0.999
CR	0 (0.0%)	0 (0.0%)	
PR	12 (85.7%)	13 (86.7%)	
SD	2 (14.3%)	2 (13.3%)	
PD	0 (0.0%)	0 (0.0%)	
Overall response rate	12 (85.7%)	13 (86.7%)	> 0.999

Abbreviations: NK = natural killer, CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease

Supplementary Table S2. Baseline characteristics of patients according to dynamic changes in NK cell activity

	High baseline NK group (n=19)	Recovered NK group (n=9)	Persistently low NK group (n=10)	P value
Age (mean±SD)	63.47±9.03	62.56±10.62	62.20±8.24	0.931
Sex				0.015
Female	2 (10.5%)	5 (55.6%)	1 (10.0%)	
Male	17 (89.5%)	4 (44.4%)	9 (90.0%)	
HER2 status				0.222
IHC 2+ / FISH+	3 (15.8%)	1 (11.1%)	4 (40.0%)	
IHC 3+	16 (84.2%)	8 (88.9%)	6 (60.0%)	
Risk group				0.033
Good	9 (47.4%)	3 (33.3%)	0 (0.0%)	
Moderate or poor	10 (52.6%)	6 (66.7%)	10 (100.0%)	
ECOG PS				0.831
0–1	18 (94.7%)	8 (88.9%)	9 (90.0%)	
≥ 2	1 (5.3%)	1 (11.1%)	1 (10.0%)	
Prior gastrectomy				0.121
No	9 (47.4%)	4 (44.4%)	1 (10.0%)	
Yes	10 (52.6%)	5 (55.6%)	9 (90.0%)	
Peritoneal metastasis				0.149
No	11 (57.9%)	4 (44.4%)	2 (20.0%)	
Yes	8 (42.1%)	5 (55.6%)	8 (80.0%)	
Bone metastasis				0.831
No	18 (94.7%)	8 (88.9%)	9 (90.0%)	
Yes	1 (5.3%)	1 (11.1%)	1 (10.0%)	
Lung metastasis				0.831
No	18 (94.7%)	8 (88.9%)	9 (90.0%)	
Yes	1 (5.3%)	1 (11.1%)	1 (10.0%)	
Elevated ALP				0.932
No	12 (63.2%)	6 (66.7%)	7 (70.0%)	
Yes	7 (36.8%)	3 (33.3%)	3 (30.0%)	
Elevated total bilirubin				0.052

No	19 (100.0%)	9 (100.0%)	8 (80.0%)	
Yes	0 (0.0%)	0 (0.0%)	2 (20.0%)	
Hypoalbuminemia				
No	15 (78.9%)	7 (77.8%)	5 (50.0%)	
Yes	4 (21.1%)	2 (22.2%)	5 (50.0%)	
NLR, median (IQR)	1.92 (1.50, 2.40)	3.06 (2.18, 4.94)	2.92 (2.42, 3.69)	0.053

Abbreviations: NK cell = natural killer cell, SD = standard deviation, IHC = immunohistochemistry, FISH = fluorescence in situ hybridization, ECOG PS = Eastern Cooperative Oncology Group Performance Status, ALP = alkaline phosphatase, NLR = neutrophil to lymphocyte ratio, IQR = interquartile range, FISH = fluorescence in situ hybridization

Supplementary Table S3. Best response to fluoropyrimidine-platinum doublet plus trastuzumab according to dynamic change in NK cell activity in patients with measurable disease (n = 29)

	High baseline NK group (n = 14)	Recovered NK group (n = 8)	Persistently low NK group (n = 7)	P-value
Best response				>0.999
CR	0 (0.0%)	0 (0.0%)	0 (0.0%)	
PR	12 (85.7%)	7 (87.5%)	6 (85.7%)	
SD	2 (14.3%)	1 (12.5%)	1 (14.3%)	
PD	0 (0.0%)	0 (0.0%)	0 (0.0%)	
Overall response rate	12 (85.7%)	7 (87.5%)	6 (85.7%)	>0.999

Abbreviations: NK cell = natural killer cell, CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease